Recently, programmed cell death 1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) inhibitors (alone or in combination) have been shown to result in higher survival rates than standard chemotherapy in patients with advanced NSCLC.2, 3, 4, 5, 6, 7, 8. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.